Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity

Cell Death and Differentiation

Volumn 14, Issue 3, 2007, Pages 480-488

  Strauss, G ^a   Osen, W ^b   Knape, I ^a   Jacobsen, E M ^a   Muller S M ^c   Debatin, K M ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; BACTERIAL ANTIGEN; CYTOTOXIC ANTIBODY; FAS ANTIGEN; HLA A1 ANTIGEN; MEMBRANE ENZYME; VIRUS ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL MATURATION; CELLULAR IMMUNITY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; CELL MEMBRANE; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; HERPESVIRUS 4, HUMAN; HLA-A1 ANTIGEN; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, CELLULAR; ISOANTIGENS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TRANSFECTION;

BACTERIA (MICROORGANISMS);

EID: 33847066615     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402019     Document Type: Article

References (40)

1. Rieux-Laucat F. Inherited and acquired death receptor defects in human Autoimmune Lymphoproliferative Syndrome. Curr Dir Autoimmun 2006; 9: 18-36.
2. Budd RC. Death receptors couple to both cell proliferation and apoptosis. J Clin Invest 2002; 109: 437-441.
3. Chen M, Wang YH, Wang Y, Huang L, Sandoval H, Liu YJ et al. Dendritic cell apoptosis in the maintenance of immune tolerance. Science 2006; 311: 1160-1164.
4. Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000; 1: 469-474.
5. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC et al. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
6. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192.
7. Lau HT, Yu M, Fontana A, Stoeckert Jr CJ. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109-112.
8. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738-743.
9. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
10. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997; 3: 165-170.
11. Behrens CK, Igney FH, Arnold B, Moller P, Krammer PH. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice. J Immunol 2001; 166: 3240-3247.
12. Igney FH, Behrens CK, Krammer PH. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo. Int J Cancer 2005; 113: 78-87.
13. Askenasy N, Yolcu ES, Yaniv I, Shirwan H. Induction of tolerance using Fas ligand: A double-edged immunomodulator. Blood 2005; 105: 1396-1404.
14. Matsue H, Matsue K, Walters M, Okumura K, Yagita H, Takashima A. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat Med 1999; 5: 930-937.
15. Wolfe T, Asseman C, Hughes A, Matsue H, Takashima A, von Herrath MG. Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection. J Immunol 2002; 169: 4867-4872.
16. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993; 5: 625-630.
17. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31-36.
18. Aoki K, Kurooka M, Chen JJ, Petryniak J, Nabel EG, Nabel GJ. Extracellular matrix interacts with soluble CD95L: Retention and enhancement of cytotoxicity. Nat Immunol 2001; 2: 333-337.
19. Kang SM, Braat D, Schneider DB, O'Rourke RW, Lin Z, Ascher NL et al. A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. Transplantation 2000; 69: 1813-1817.
20. Nafe C, Cao YJ, Quinones A, Dobberstein KU, Kramm CM, Rainov NG. Expression of mutant non-cleavable Fas ligand on retrovirus packaging cells causes apoptosis of immunocompetent cells and improves prodrug activation gene therapy in a malignant glioma model. Life Sci 2003; 73: 1847-1860.
21. Zemmour J, Little AM, Schendel DJ, Parham P. The HLA-A,B 'negative' mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol 1992; 148: 1941-1948.
22. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405-431.
23. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002; 128: 255-266.
24. Smith KD, Lutz CT. Peptide-dependent expression of HLA-B7 on antigen processing-deficient T2 cells. J Immunol 1996; 156: 3755-3764.
25. Hoves S, Krause SW, Halbritter D, Zhang HG, Mountz JD, Scholmerich J et al. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC. J Immunol 2003; 170: 5406-5413.
26. Dulat HJ, von Grumbkow C, Baars W, Schroder N, Wonigeit K, Schwinzer R. Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells. Eur J Immunol 2001; 31: 2217-2226.
27. Igney FH, Behrens CK, Krammer PH. Tumor counterattack - concept and reality. Eur J Immunol 2000; 30: 725-731.
28. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 1996; 274: 1363-1366.
29. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK et al. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-5675.
30. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4: 1287-1292.
31. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186: 2045-2050.
32. Walker LS, McLeod JD, Boulougouris G, Patel YI, Ellwood CN, Hall ND et al. Lack of activation induced cell death in human T blasts despite CD95L up-regulation: Protection from apoptosis by MEK signalling. Immunology 1999; 98: 569-575.
33. Kirchhoff S, Muller WW, Li-Weber M, Krammer PH. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur J Immunol 2000; 30: 2765-2774.
34. Holmstrom TH, Schmitz I, Soderstrom TS, Poukkula M, Johnson VL, Chow SC et al. MAPK/ERK signaling in activated T cells inhibits CD95/ Fas-mediated apoptosis downstream of DISC assembly. Embo J 2000; 19: 5418-5428.
35. Desbarats J, Wade T, Wade WF, Newell MK. Dichotomy between naive and memory CD4(+) T cell responses to Fas engagement. Proc Natl Acad Sci USA 1999; 96: 8104-8109.
36. Lu L, Qian S, Hershberger PA, Rudert WA, Lynch DH, Thomson AW. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol 1997; 158: 5676-5684.
37. Kusuhara M, Matsue H. Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections. Exp Dermatol 2005; 14: 273-280.
38. Buonocore S, Flamand V, Claessen N, Heeringa P, Goldman M, Florquin S. Dendritic cells overexpressing Fas-ligand induce pulmonary vasculitis in mice. Clin Exp Immunol 2004; 137: 74-80.
39. Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003; 102: 2292-2299.
40. Strauss G, Knape I, Melzner I, Debatin KM. Constitutive caspase activation and impaired death-inducing signaling complex formation in CD95-resistant, long-term activated, antigen-specific T cells. J Immunol 2003; 171: 1172-1182.